ALLR (Allarity Therapeutics) Book Value per Share: $0.44 (As of Mar. 2026)


ALLR Allarity Therapeutics Inc ALLR
26 GF Score
Price $1.17
! 2 Warning Signs
View Full Analysis

What is Allarity Therapeutics Book Value per Share?

Allarity Therapeutics ALLR -2.91% 26 Book Value per Share is $0.44 as of Mar. 2026. GuruFocus rates ALLR with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Allarity Therapeutics's book value per share for the quarter that ended in Mar. 2026 was $0.44.

During the past 12 months, Allarity Therapeutics's average Book Value Per Share Growth Rate was -60.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Allarity Therapeutics's current price is $1.165. Its book value per share for the quarter that ended in Mar. 2026 was $0.44. Hence, today's PB Ratio of Allarity Therapeutics is 2.67.

During the past 7 years, the highest P/B Ratio of Allarity Therapeutics was 4.05. The lowest was 1.36. And the median was 2.70.


Allarity Therapeutics  (NAS:ALLR) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Allarity Therapeutics Book Value per Share Related Terms


Allarity Therapeutics Book Value per Share Historical Data

* Premium members only.

The historical data trend for Allarity Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allarity Therapeutics Book Value per Share Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Book Value per Share
Get a 7-Day Free Trial 0.00 -113.00 -449.30 1.62 0.61

Allarity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.83 0.75 0.61 0.44

ALLR vs NCEL, LPCN, PTN: Book Value per Share Comparison

For the Biotechnology subindustry, Allarity Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allarity Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Allarity Therapeutics's PB Ratio falls into.


ALLR
26GF Score
Allarity Therapeutics Inc ALLR
Book Value per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allarity Therapeutics Book Value per Share Calculation

Allarity Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(9.83-0.00)/16.08
=0.61

Allarity Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2026 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(6.92-0.00)/15.82
=0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $0.44 mean?
Allarity Therapeutics (ALLR) has a Book Value per Share of $0.44 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Allarity Therapeutics and its competitors.
Is Allarity Therapeutics' Book Value per Share too high?
Allarity Therapeutics' current Book Value per Share is $0.44. Overall, Allarity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' Book Value per Share compare to NCEL and LPCN?
Allarity Therapeutics' Book Value per Share of $0.44 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Allarity Therapeutics and its competitors. Allarity Therapeutics's current Book Value per Share is $0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current Book Value per Share of $0.44. The current Book Value per Share is $0.44. Allarity Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current Book Value per Share is $0.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allarity Therapeutics Business Description

Address 123 East Tarpon Avenue, Tarpon Springs, FL, USA, 34689
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
26GF Score

Get the complete analysis for ALLR

Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.17
Price